Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION Disproportionate reporting signal workbook arrived with a CMO 483 that maps to the NDA CMC module for clinical-development physician. That is a Pharma & Life Sciences Clinical and Evidence Strategy decision on to drop a secondary in a biologics company planning a biosimilar pathway.

DECISION Clinical-development physician in a biologics company planning a biosimilar pathway must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using disproportionate reporting signal workbook after a CMO 483 that maps to the NDA CMC module.

HYPOTHESES TO TEST 1. A CMO 483 that maps to the NDA CMC module is already priced into disproportionate reporting signal workbook; clinical-development physician can take Proceed under protocol on to drop a secondary inside a biologics company planning a biosimilar pathway. 2. A CMO 483 that maps to the NDA CMC module is the event in disproportionate reporting signal workbook that forces Pause the pathway rather than Proceed under protocol for this Clinical and Evidence Strategy file. 3. Disproportionate reporting signal workbook shows a one-file miss after a CMO 483 that maps to the NDA CMC module, not a Pharma & Life Sciences program failure across a biologics company planning a biosimilar pathway. 4. To drop a secondary cannot be closed from disproportionate reporting signal workbook after a CMO 483 that maps to the NDA CMC module; clinical-development physician should keep Hold in force.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 3. Check whether disproportionate reporting signal workbook supports the labeled claim clinical-development physician would keep. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read disproportionate reporting signal workbook against a CMO 483 that maps to the NDA CMC module and write the one fact that would move to drop a secondary for clinical-development physician.

RECOMMENDATION Clinical-development physician should take Pause the pathway on to drop a secondary unless disproportionate reporting signal workbook after a CMO 483 that maps to the NDA CMC module already proves Proceed under protocol for this Clinical and Evidence Strategy packet in a biologics company planning a biosimilar pathway. Keep Escalate safety review live only while disproportionate reporting signal workbook is missing the decision to drop a secondary turns on. The working test on disproportionate reporting signal workbook is whether Separate an isolated adverse event from a systemic quality issue..

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in disproportionate reporting signal workbook, then the action for clinical-development physician - Hypothesis scorecard against disproportionate reporting signal workbook: supported / rejected / untestable - Missing page in disproportionate reporting signal workbook after a CMO 483 that maps to the NDA CMC module, if any - Regulatory or exam hook Clinical and Evidence Strategy would cite